ArticleInternational journal of oncology2018

HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.

Zhongbo Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.